Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial
By activating three hormone receptorsGIP, GLP-1, and glucagonit may offer a more comprehensive approach to treating obesity and type 2 diabetes compared to medications targeting fewer receptors
23 These symptoms can be severe in some patients, resulting in a pause of dose escalation, and if intolerable GI symptoms continue, a dose adjustment to the previous lower dose or a switch to an alternative GLP-1 RA should be considered
Geller, G
Because of this, your clinician might suggest waiting before evaluating results, so the medication has time to reach its full effect
Keep a detailed record of your symptoms, including when they started, their frequency, and their severity